Vertex shares rise after JPM sets Overweight rating
J.P. Morgan upgraded Vertex Pharmaceuticals to an Overweight rating and set a December 2027 price target of $560. VRTX stock was up 1.6% premarket.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.